They chose 14 studies of more than 50 available. Their method for screening studies looks biased towards finding an inconclusive result.
Bear in mind that 'bias' with regard to ivermectin is less likely to come from doctors than it is pharma companies. Doctors stand to gain nothing from the efficacy of ivermectin since it's a generic drug on the market since 1987. Pharma companies have a lot to lose if it's proven effective.
To control for bias one ought to look at larger sample sizes. And each time that happens there's a significant result.
Bear in mind that 'bias' with regard to ivermectin is less likely to come from doctors than it is pharma companies. Doctors stand to gain nothing from the efficacy of ivermectin since it's a generic drug on the market since 1987. Pharma companies have a lot to lose if it's proven effective.
To control for bias one ought to look at larger sample sizes. And each time that happens there's a significant result.